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1. Introduction 
1.1 Definition of breast density 
Breast density, or mammographic parenchymal pattern, refers to the radiographic appearance of 
the female breast. The individual mammographic picture arises from variations in x-ray attenuation 
of different types of tissue. Fat, which is radiolucent, appears dark on a mammogram. Epithelial 
and stromal tissues on the other hand, appear white or radiodense and are collectively referred to 
as “mammographic density”. As stroma is present in much larger quantities than epithelium, it 
accounts for most of the radiological density (1).  
The higher a woman‟s breast density, the greater is her associated risk to develop breast cancer. 
Breast cancer is the most common cancer in women and a leading cause of death in nearly all 
developed countries. Several breast cancer risk factors such as increasing age, late menopause, 
early menarche or family history of breast cancer (among others) have been known for many 
years, whereas mammographic breast density is a new, recently established as independent, risk 
factor. There is now a substantial body of evidence describing an association between variations in 
mammographic parenchymal patterns and differences in breast cancer risk. Studies report risk 
estimates up to 6.0, making breast density one of the strongest risk factors for breast cancer (2-4).  
However, there is no general agreement on what causes some women‟s breast to be denser than 
others and a reason or biological mechanism for the positive association to breast cancer risk has 
yet to be found. 
1.1.1 Breast density and breast cancer risk 
The first article about the relationship between breast density and breast cancer risk was published 
by Dr. John Wolfe in 1976 (5). He applied a method of classification of parenchymal patterns using 
qualitative criteria. Based on four patterns designated N1 (primarily fatty), P1 (≤ 25% prominent 
ducts), P2 (> 25% prominent ducts) and DY (dense fibroglandular tissue), he was the first to 
describe an increased breast cancer risk for women with high breast density. For years his 
hypothesis was debated and distrusted in literature until many publications confirmed his findings 
in the late 1990s. Thereafter high-quality epidemiological studies explored the risk-density 
relationship. As a minimum, 15 cohort studies, or nested case-control studies confirmed that 
Wolfe‟s classification of mammographic patterns is associated with a difference in breast cancer 
risk. One group of opponents of Wolfe‟s theory proposed what later became known as the 
“masking hypothesis” (6). They suggested that the apparent excess of cancer cases in the high 
density group during follow up is simply due to a decrease in mammographic sensitivity. However, 
in subjects reexamined over a long period of time, these effects of masking will be short-lived. 
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Among others, Brisson et al. showed in one of their studies that the increased risk associated with 
greater mammographic density persist for up to 9 years after screening (7). This argues against 
detection bias as the sole cause of the observed increase of cancer.  
In a systemic meta-analysis of data for over 14.000 breast cancer cases and 226.000 noncases 
from 42 different studies, McCormack et al. found a consistent association of breast density with 
breast cancer risk (8). The strength of the association of breast density with cancer risk is greater 
than for most other established risk factors, except of age and genetic factors. The total dense 
area on a mammogram and percent density are both associated to higher breast cancer risk, 
however, percent density showes a stronger association (9). Several quantitative studies of breast 
density and cancer risk have been published applying visual estimation of the dense area, 
planimetry, or computer-assisted methods in digitized images. Although category definitions might 
vary, the odds ratio for developing breast cancer for very dense breasts compared with fatty 
breasts ranges from 1.8 to 6.0, with nearly all studies reporting risk estimates of 4.0 or higher (3, 9, 
10). This risk is larger than is found with most other risk factors for breast cancer. Additionally, 
breast density accounts for a large number of cancer cases. Attributable risk has been estimated in 
a report of McCormack et al.; for the 20% and 10% of premenopausal women, who had densities 
over 50%-74% and ≥75% correspondingly, the population attributable fraction was 42.8% and 
26.7% respectively. For postmenopausal women the respective equivalent fractions were 9.8% 
and 23.2% (for 10% and 3% of women with densities of 50-74% and ≥ 75%) (8). Breast density is 
unique in its potential of being modified by hormonal (11) and dietary interventions (12).  
Nevertheless, the reasons or biological mechanisms for this positive association have yet to be 
identified in detail. Besides, there is no general agreement on the causes of dense breasts and we 
do not know if a reduction in breast density would mean a reduction in risk, too.  
1.1.2 Breast density measurement technique 
To assess mammographic breast density, four principal methods have been used to date. 
Examples of breast density measurements can be seen in figure 1. As the mammographic 
measurement technique changed from xeromammography to screen-film mammography (which 
emphasized density differences in breast parenchyma rather than the visibility of prominent ducts) 
four categories of overall breast density replaced the four Wolfe parenchymal patterns as an index 
of parenchymal content. Because of difficulties in consistently applying a qualitative classification 
and variations in reproducibility (13, 14) researchers subsequently moved towards quantitative 
measures of mammographic density. Since the early 1980s, different quantitative mammographic 
methods of measuring breast density were developed and performed. To date, nine studies have 
used quantitative methods to find a risk of four or greater comparing extreme categories of the 
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density classifications used (15). In clinical practice, the most common method of classification is 
the American College of Radiology's four category Breast Imaging Reporting and Data System (BI-
RADS) rating (extremely dense, heterogeneously dense, scattered fibroglandular tissue and 
almost entirely fat) (16). However, this classification, mainly used to inform referring physicians of 
the amount of decline in mammographic sensitivity with increasing breast density, was not 
intended to serve as a method of measuring breast density. 
The only moderate interobserver agreement with an overall kappa value of 0.4-0.6 (17, 18) might 
be due to the lack of well-defined categories. Nevertheless, the great advantage of this 
classification is its wide and consistent use, which allows for an analysis of large populations. 
Concerning the interobserver agreement, more consistent quantitative computer-assisted density 
measurements have been developed. The earliest computer-assisted planimetry was used in 1987 
(19). Agreement with this method was 70% to 94% (19, 20). Following this technique, film 
mammograms have been digitized and measurements are now being taken with more consistent 
computer systems. With either a mouse, or a digital segmentation of the mammogram the area of 
breast parenchyma and the total area of the breast are outlined and percent density values are 
computed. Interreader reliability for quantitative estimation by a radiologist its intermediate 
(intraclass correlation coefficient (ICC)~0.7) (21) and good for the computer-assisted measurement 
(ICC~0.9) (22).  
Altough quantitative methods are more time consuming than qualitative estimations, they are more 
reliable and can additionally provide information about the separate components of the ratio of 
percent density. In this study, computer-assisted density measurements were used, as described 
in detail later.  
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Fig. 1  Examples of mammographic breast density. Very low density (A), 
Medium dense breast (B), Extremely dense breast (C). 
1.1.3 Histological basis for mammographic density 
In order to identify biological plausible mechanisms through which breast density might be 
associated to breast cancer, several studies have examined the association between the 
mammographic and histopathological appearance of the female breast. The principal features of 
these studies are summarized in table 9.1 and table 9.2. 
The two types of tissue that give rise to mammographically dense breasts are stroma and 
epithelium, where the majority of the dense part is comprised of stromal tissue. Numerous reports 
describe a positive association between density and proliferative lesions of stroma and epithelium 
(23, 24). Especially hyperplasia, atypical hyperplasia, carcinoma in situ (CIS) and fibrocycstic 
changes have been shown to be positively associated to denser breasts (25-27). In the study 
published by Bartow et al., material derived from a forensic autopsy series was utilized preparing 
radiographs from sectioned specimens (s.c. mastectomy), reporting a positive correlation between 
high density and intraductal epithelial hyperplasia and lobular microcalcification (28). Three other 
cross-sectional studies compared the histological findings of breast biopsies and radiological 
qualitative classification of the whole breast and also found density to be positively associated with 
epithelial proliferation. They also report an association with high risk patterns such as atypia of the 
ductal type (24, 29, 30). Lee et al. found a direct relationship between the degree of 
mammographic density and cytological abnormality in nipple aspirate fluid (NAF) (31). Boyd et al. 
described a strong association between mammographic densities and the risk of developing 
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proliferative lesions in the breast epithelium. Compared with women showing no mammographic 
densities, women with the most extensive densities (i.e., occupying > 75% of the breast volume) 
had a 9.7 times greater risk of developing carcinoma in situ or atypical hyperplasia, a 12.2 times 
greater risk of developing hyperplasia without atypia and a 3.1 times greater risk of developing 
nonproliferative disease (10). On the other hand, Moskowitz et al. as well as Bland et al. did not 
find a significant positive association of high mammographic densities and hyperplasia in biopsies 
from women with benign breast disease (32, 33). In accordance with these findings, Fisher et al. 
who analyzed samples from breast cancer and fibrocystic breast disease patients did not report a 
significant correlation (34). Arthur et al. did not find an association of epithelial hyperplasia or CIS 
with Wolfe‟s patterns, but reported an association of fibrosis in the interlobular stroma with high 
density patterns (35).  
Although not fully consistent, these findings agree with the hypothesis that breast density might be 
associated to breast cancer risk through mechanisms contributing to proliferative activities of 
breast tissue. Some researchers hypothesize that the breast cancer risk is dependent of the 
amount of mammary gland cells, or mammary tissue-specific stemm cells. They argue that dense 
breasts harvest more glandular tissue and ,therefore, more cells with the potential to transform into 
malignant cells (36). Breast density might therefore just reflect the number of glandular cells and 
therefore an increased breast cancer risk.  
Further evidence that the breast tissue responsible for mammographic densities is responsive to 
hormonal influences is derived from reports about associations of breast density to other risk 
factors of breast cancer. Some of these are being described in the following section. 
1.1.4 Determinants of breast density 
Mammographic densisites have consistently been found to be associated with other breast cancer 
risk factors, including endogenous hormonal factors such as menopause, parity and number of live 
births, as well as exogenous hormonal factors such as hormone replacement therapy (HRT). 
Among others, density is inversely associated with increasing age and body mass index (BMI). 
Family history of breast cancer, on the other hand, is associated with more extensive densities. 
The evidence for some of these associations, relevant for our study, is being described in the 
following sections. 
1.1.4.1 Age  
On of the most important risk factors for breast cancer, a woman‟s age, is closely associated with 
breast density. The amount of dense tissue has been shown to decline with age, contradictory to 
an increase of breast cancer incidence over time (15). Few longitudinal studies of mammographic 
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densities have been conducted. One of the few longitudinal studies, estimated the average annual 
reduction in percent density as 1% (37). In a study of Maskarinec et al., it has been demonstrated 
that the age related decline of breast density was highest between age 45 and 55 and changed 
very little after age 65 (38). Others also found that women with a higher initial percent density had 
a faster rate of decrease in breast density over time (39). 
The decline in density with age may seem paradoxical, as breast cancer incidence in contrast, 
increases with age. However, the apparent paradox might be resolved by reference to a model of 
breast cancer incidence as proposed by Pike and colleagues (40), who showed that cumulative 
breast tissue exposure to hormones and growth factors rather than the chronological age 
describes the age-incidence curve for breast cancer. Exposure is greatest at the age of menarche 
and consistently decreases with pregnancy, perimenopausal period and finally in menopause. 
Corresponding to this model, as stated by McCormack et al., cumulative exposure to breast density 
would be the pertinent risk factor for which density at a given age is a good proxy. It might be 
density at a given age rather than density per se that is related to breast cancer. 
 
1.1.4.2 Menopause 
Mammographic density has also been shown to be significantly higher in premenopausal than 
postmenopausal women. Density decreases during menopause. 34% of women age 75 to 79 have 
breasts mainly comprised of fatty tissue, compared with only 11% of women age 25 to 29 years. 
Equally, only 30% of women age 75 to 79 have a breast density of 50% or greater (41). On the 
other hand, it has been argued that these lesser values in postmenopausal density are simply a 
result of the decrease in density with age since most evidence is derived from density measures of 
different women (rather than on the change in the mammograms of one individual). To address this 
problem, Boyd et al. conducted a longitudinal study of the effects of menopause within subjects of 
the NBSS, directly comparing changes occurring in women who experienced menopause with an 
age-matched group who remained premenopausal. Their findings demonstrate that menopause 
has effects on density that, over the same period of time, are greater than the effects of age 
alone (37). Compared with women who remained premenopausal, percentage of breast density 
decreased to a significantly greater extent in women who underwent menopause (difference in 
change = -3.26 percentage points, p=0.004) during the same time period.  On the contrary, Guthrie 
et al. did not find a significant effect of menopausal change on the amount of dense tissue after 
controlling for age (42). In their longitudinal study, they report a lower percent mammographic 
density in postmenopausal women, but no significant increase in dense area. Therefore, they 
argue, like other researchers, that the decrease in percent density might simply be explained by an 
increase in the amount of fatty, nondense tissue. Nevertheless, in results of the NBSS study and 
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others, the decrease in percent density is due to both, an increase in the area of nondense tissue 
as well as a reduction in the area of radiologically dense tissue (37). In conclusion, breast density 
does decline significantly with menopause. This could be explained by the biological process of 
menopause - the consequence of decrease in the levels of endogenous hormones in the 
perimenopausal period results in regression of glandular and stromal elements and in replacement 
by radiolucent fatty tissue.  
 
1.1.4.3 Hormone replacement therapy  
In agreement with the hypothesis that breast density is influenced by hormonal changes, it has 
been shown in various studies that combined HRT (with a progesterone and estrogen regimen) 
increases breast density (43, 44). Estrogen only, on the other hand, has just a weak influence on 
mammographic breast density (44-46). Exogenous hormone treatment seems to stop or delay the 
progress of involution during menopause, resulting in an increase in mammographic density. In a 
study of Laya et al. it has been demonstrated that densities increased about 6.7% (mean increase; 
p=0.03)  in 30 (73%) of the 41 subjects undergoing continuous combined HRT for 1 year compared 
with baseline density values (43). They also showed an inverse relationship between baseline 
density and change in percentage density; the lower the baseline density percentage, the greater 
the change. Greendale et al. assessed the effects of conjugated equine estrogens (CEE) alone 
and CEE combined with three progestin regimens on breast density in a randomized, long-term, 
placebo-controlled and double-blinded trial. They report an incrase in density in approximately 8% 
of estrogen users and 19% to 24% of estrogen-progestin users.  Compared to CEE-only patients, 
combined HRT users had a 7-fold to 13-fold increased risk for developing denser breasts (47).  
 
1.1.4.4 Estrogen exposure  
Together with the knowledge of estrogen being a central player in the etiology of breast cancer, 
these findings suggest that breast density might be a marker for estrogen exposure.  
Nevertheless, there are ambiguous results from studies addressing this association. Two studies 
did not find an association between estrogen serum levels and breast density (48-50). Similarly, 
Frankenfeld et al. detected an association with sex hormone binding globulin, but no association 
with free estradiol levels. 
Given the role of estrogen receptors in estrogen response of breast tissue, expressions of these 
receptors in normal breast tissue could be related to breast cancer risk and incidence. However, 
few studies address these receptors in their relation to breast density. Results of one previous 
study show a positive association of breast density to both ER-positive and ER-negative breast 
cancer cases (51). Furthermore, bone mineral density (BMD), believed to be a marker of 
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cumulative estrogen exposure did not show an association with mammographic density (52). In 
accordance to the association of density with HRT, several studies agree in their findings that 
density is noticeably higher during the luteal phase of a woman‟s cycle, which is characterized by 
an increase in progesterone as well as estrogen levels (53-55). Examining continuous breast 
density measures in the same women at different phases of their menstrual cycle, Ursin et al. 
observed a statistically significant increase of 1.2% in breast density during the luteal phase. 
Endogenous progesterone was found to be related to mammographic density in one report among 
premenopausal women (56). Moreover, studies show a decrease in mammographic density after 
endocrine therapy with tamoxifen, a selective ER modulator with antiestrogenic effects (57, 58). 
This effect was most pronounced in premenopausal women and has been found in treatment with 
raloxifene, an analog of tamoxifen, too (59). In addition, nulliparous women and those with a later 
age at first birth have been shown to have significantly denser breasts than women who had 
children at a young age (60, 61). 
One reason for the discrepancy in the results might be the use of different measures addressing 
the estrogen exposure of breast tissue. It is known that estrogen levels in the breast tissue differ 
from circulating hormones or plasma levels. Local estrogen concentrations in benign and malignant 
breast tissue were reported to be higher than plasma levels (62, 63). The exact correlation though 
has only inconsistently been reported. Furthermore, the inconsistent findings about the association 
to endogenous and exogenous estrogens and breast density could possibly be related to the 
expression of hormonal receptors, which are essential in the response to circulating estrogens. 
 
1.1.4.5 Genetics and ethnicity 
Genetics partially determine breast density as shown in a study by Boyd et al. (64). They report a 
2-fold higher correlation between monozygotic compared to dizygotic twins, whereas Pankow et al. 
found significant correlations with breast density between sisters in their cohort study (65). There 
are known genetic factors that influence breast density variation such as variants in the CYP1A2 
and catechol-O-methyltransferase genes, both being involved in estrogen metabolism (66-68). 
Among others, Crest et al. found that having a family history of breast cancer is strongly associated 
with higher breast density, especially when relatives were genetically similar (69). 
Since race and ethnicity have a significant impact on breast cancer incidence and mortality, 
several studies have addressed the question, whether variations in breast density could explain 
these differences. Ursin et al., as well as Maskarinec et al. report similar effects of density on 
breast cancer in whites and Asian Americans (3, 70). These findings are consistent with the trends 
in breast cancer incidence among Asians living in the United States. Maskarinec et al. found 
percent density among Japanese women living in Hawaii to be significantly higher than among 
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Japanese women living in Japan (71). Conflicting results have been published, such as studies 
reporting higher breast density among Asian women (72). However, these differences disappeared 
after adjustment for BMI. Therefore, studies suggest that the size of the dense area is a better 
indicator of ethnic differences than percent density.  
1.2 Hormonal receptors (ERα, ERβ and PR) 
The biological activities of endogenous and exogenous sex steroids on breast tissue are mediated 
by nuclear estrogen receptors alpha and beta (ERα and ERβ) and progesterone receptor (PR). 
Estrogen plays a crucial role in regulating growth and differentiation of the mammary gland and is a 
key player in the development and progression of breast cancer (73). Activation of estrogen 
receptors leads to expression of proteins associated with cellular proliferation and tumor. The 
dysregulation of ER is related to an improved overall survival and favorable response to endocrine 
therapy such as anti-estrogen tamoxifen.  Data suggest that ER expression of normal breast tissue 
is fairly consistent (74). The main clinical application of ERα measurement in breast cancer is to 
determine prognosis and predict response to endocrine therapy. Tumors rich in ERα have a 60 to 
70% chance of responding to first line endocrine treatment (75).   
ERβ also plays a role in carcinogenesis, progression and hormone dependency of breast cancers, 
however associations between expression of ERβ and ERα have inconsistently been 
described (76, 77). 
Only one prior study addressed the association between breast density and ERα status in breast 
tissue. In noncancerours tissue from mastectomies they did not find an association between ER 
expression and breast density. However, the sample size was only n=56 (78). This study did not 
find an association between density and PR expression. Progesterone, another major player in 
mammary gland biology, acts in conjunction with estrogen through its specific intranuclear 
progesterone receptors (PRA and PRB). Abnormal ratios of these isoforms may play some part in 
the initiation of breast carcinogenesis (79, 80). The prognostic and predictive values of total PR 
status are similar to ER status, but weaker in terms of prediction of endocrine therapy response 
(74).  
1.3 Proliferation markers (Ki-67, PCNA and HER2/neu) 
Proliferation of tumor cells is an important prognostic indicator. The estimation of growth fraction 
can be evaluated by immunocytochemical staining with antibodies against proliferation-associated 
antigens. One of the antibodies frequently used for this purpose is Ki-67 (81, 82). It reacts with a 
nuclear antigen present in G1, S and G2 phases, reaching a maximum in the early S phase and 
disappearing during mitosis. PCNA, proliferating cell nuclear antigen, is an accessory protein for 
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DNA polymerase and has a longer half-life than Ki-67. Therefore, it tends to overestimate 
proliferation but provides a longer-term, cumulative assessment of proliferative activity and is 
valuable for tissues with only low number of proliferating cells (83, 84). Together, these two 
markers provide two complementary measures of proliferation.  
Their relation to breast density has been assessed in two prior studies. One reports a positive 
association of breast density to expression of Ki-67 in ducts of breast tissue (78). The other study 
conversely did not find a correlation between Ki-67 expression in FNA tissue samples and breast 
density (85). To date, PCNA has not been assessed in its relation to breast density.  
Another receptor, distantly related to proliferation, is the tyrosine kinase HER-2/neu of the 
epidermal growth factor family. Amplification of the gene encoding ErbB2/HER2 is detected in 
approximately 20% of breast tumors. It is correlated with dramatic overexpression of the receptor, 
an aggressive phenotype of tumors as well as poor clinical prognosis (86). Trastuzumab, a HER-2 
specific recombinant humanized antibody was the first biologic approved for treatment of 
metastatic breast cancer. This receptor had not yet been analyzed in its relation to breast density. 
1.4 Stromal histopathology and matrix metalloproteinases (MMPs) 
As mentioned earlier, the main component of the radiologically dense breast is comprised of 
stromal tissue whereas epithelial cells only constitute about 5% of breast tissue. In breast cancer 
patients, increased amounts of collagen, the main component of stromal tissue, have been shown 
through many studies to be associated with breast density (87-89). Growing evidence supports the 
notions that altered regulation of the stroma, or extracellular matrix (ECM), contributes to 
neoplastic progression and that disruptions in the ECM may precede epithelial changes (90). One 
group of enzymes, involved in the remodeling of extracellular matrix (ECM) are matrix 
metalloproteinases (MMPs). They constitute a family of over 20 zinc-dependent endopeptidases 
that have classically been viewed as being secreted by tumor cells to degrade the basement 
membrane and ECM components to facilitate tumor invasion and formation of metastasis. Today 
we know that MMPs contribute to multiple steps of tumor promotion, angiogenesis and the 
establishment of metastatic lesions. They are synthesized by tumor cells, as well as by the 
surrounding host stromal cells such as fibroblasts, endothelial and also infiltrating inflammatory 
cells (91-93). MMPs are produced as latent proenzymes, stored in inflammatory cells, anchored to 
the cell surface or within the ECM. Physiologic MMP levels are low, but their expression is rapidly 
up-regulated when tissues undergo remodeling such as inflammation, wound healing and 
tumorigenesis (94, 95).  
Overexpression and unrestrained activity of MMPs have as well been linked to malignant 
conversion of tumor cells (96). MMPs are universally expressed during tumor progression and 
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have been documented in essentially every human tumor entity, including breast cancer (91). 
There is considerable evidence supporting a role of MMPs in early stages of tumor onset and 
primary tumor growth. In particular, MMP-3 and MMP-9 have been reported to be involved in 
mammary carcinogenesis (97). Although the matrix-degrading properties of MMPs are important, 
they alone do not account for the diversity of biologic effects. The ECM is a reservoir of growth 
factors and binding proteins which effect tumor cell behavior. Most likely, the activating ability of 
MMPs on these factors is what yields to the rapid responses required for tumor growth and 
progression. For instance, the activity of insulin like growth factors (IGFs), important growth factors 
in tumor progression, is controlled by numerous extracellular binding proteins (IGFBPs) (98). 
Cleavage of these binding proteins by MMPs possibly contributes to tumor growth (99). Other 
factors activated by MMPs are promoting survival (FAS-Ligand), angiogenesis (Collagen IV, 
VEGF) and invasion (Lam-5, CD-44) (among others) (100). It is important to note that different 
MMPs contribute to tumor progression at multiple or different stages. They play important roles in 
tumorigenesis, cancer progression, invasion and metastasis through several diverse mechanisms. 
Tissue inhibitor of metalloproteinases (TIMPs 1, 2 and 3), are natural inhibitor proteins, mostly 
produced by stromal host cells and by the tumor cell itself. They form complexes with both latent 
and activated MMPs, inhibiting their enzymatic activity. 
1.5 Goals of the study 
Breast density is a strong, independent risk factor for breast cancer, which is a leading cause of 
morbidity and mortality among women in nearly all developed countries. Yet, the biological basis 
for this association is not known. Given the aforementioned inconsistent findings about proliferative 
lesions and histopathological correlates of breast density, one aim of this study was to examine the 
correlation of breast density with the expression of markers of proliferation in breast tissue. We 
measured Ki-67 expression, a widely-used indicator of cell proliferation in normal and neoplastic 
tissues and Proliferating Cell Nuclear Antigen (PCNA), which gives a cumulative assessment of 
proliferative activity and is valuable for tissues with only low numbers of proliferating cells (84). As 
risk factors that induce proliferation, hormone replacement therapy (HRT) and endogenous sex 
steroids are associated with higher breast cancer risk as well as higher breast densities (44, 77, 
78). The biological activities of endogenous and exogenous sex steroids on breast tissue are 
mediated by nuclear estrogen receptors alpha and beta (ERα and ERβ) and progesterone receptor 
(PR). To understand how hormone receptors and cell proliferation are related to mammographic 
density, this investigation examined the expression of ERα and ERβ, PR and HER2/neu. The 
effects of sex steroid hormones on the mammary gland are also mediated, at least in part, through 
interactions between stroma and epithelium (101). As stroma is present in much larger quantities 
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than epithelial tissue in the mammographically dense breast, differences in stromal qualities were 
also investigated, in particular the altered regulation of cell - extracellular matrix (ECM) interaction 
which contributes to neoplastic growth (88, 90). Finally, matrix metalloproteinases (MMPs), zinc-
dependent endopeptidases involved in remodeling of ECM, contribute to all steps of tumor 
progression, including tumor promotion, angiogenesis, and the establishment of metastatic lesions 
(102, 103). A disruption of the balance between MMPs and their natural inhibitors (TIMPs) has 
been implicated in the progression of cancer (104). To understand how stromal matrix 
metalloproteinases are related to breast density, this study examined MMP1, 3, 9, 12 and TIMP3 in 
relation to mammographic density. Finally, this study evaluates the comparably new technique of 
TMAs as a tool in epidemiologic research which characterized the pilot form of this project. The 
combination of TMA technology with population based tissue repositories offers a powerful tool for 
research regarding tumor development and progression without depletion of pathological 
specimens.  
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2. Materials and Methods 
2.1 Study population 
2.1.1 The multiethnic cohort study (MEC study) 
The study population is based on subjects who took part in the multi-ethnic-cohort (MEC) study in 
Hawaii and California and in a nested-case-control-study (NCC) for mammographic density in 
Hawaii. Participants entered the MEC study from 1993 to 1996 by completing a mail questionnaire 
that obtained information about their food frequency as well as demographic and other information. 
The MEC study investigates the association between diet and cancer in 215,251 adult men and 
women of different ethnic backgrounds (African-American, Latino, Japanese-American, Native 
Hawaiian and Caucasian). This population-based study recruited participants through driver‟s 
license, voter registration, and Health Care Financing Administration files and was approved by the 
Committee on Human Studies at the University of Hawaii. Data from the Hawaii component of the 
MEC study is linked annually to the Hawaii Department of Health vital records database and the 
statewide Hawaii Tumor Registry (HTR) to determine cancer incidence and deaths. Further details 
are provided elsewhere (105, 106). 
 
2.1.2 The nested case-control study (NCC study) 
The NCC study, on which our study population is based on, recruited all female members of the 
MEC study who resided in Hawaii and were diagnosed with primary breast cancer between cohort 
entry and December 2000 (potential cases: n=1,587). Controls were randomly selected from MEC 
Study participants who were not known to have breast cancer and frequency matched by age and 
ethnicity (107). Women with previous diagnosis of breast cancer, a history of breast augmentation 
or reduction, or without a mammogram were excluded from the study. After further exclusion of 
subjects due to death, no consent or no suitable mammogram, the final sample of the NCC study 
consisted of 607 breast cancer cases and 667 controls. Comparison of the women included in the 
study with ineligible cases showed only small differences. None of the demographic, reproductive, 
or anthropometric variables observed differed significantly at the 5% level between matched pairs 
of participants, indicating a representative sampling of the original MEC. The NCC study was 
approved by the Committee on Human Studies at the University of Hawaii. All subjects provided 
informed consent to participate for the NCC -as well as the MEC- study. 
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2.1.3 Recruitment of study subjects 
The 607 cases of the NCC-study were selected as a starting point for our study. Study subjects 
were recruited by mail with a maximum of 2 reminders. We sent out letters including information 
about the study, consent forms for the release of tissue together with a Soy Questionnaire to 430 
women. The other 177 (29.16%) women out of the NCC study were not contacted for different 
reasons. For 137 cases (22.57%), the respective hospitals were not participating in the tissue 
discharge repository organized by the HTR. Another 40 women were not contacted because of 
deaths at time of recruitment (26 women, 4.28%) and refusals (14, 2.31%). After we sent out the 
letters to potential participants, we learned about 6 deaths (0.99%) that had occurred (before the 
time of recruitment), 4 women were too ill to participate (0.66%) and some refused to partake in the 
study (37 women; 6.10%). For 52 women (8.57%) who signed a consent form, we could not 
receive any tissue for the analysis. In 30 of these cases, there was no tissue stored in the 
hospitals, 5 cases were not linked to the HTR and the tissue blocks from the remaining 17 subjects 
did not contain enough tissue to sample. We excluded all these women after obtaining this 
additional information. There were 12 women that deceased before the recruitment for our study, 
but had their tissue stored in the HTR. They were included in the study. Table 3 shows the 
numbers of women recruited and participating in the study. Our final number of cases was n=283, 
46.62% of the original NCC study participants.  
 
2.2 Data collection 
2.2.1 Anthropometric and demographic information 
Information on anthropometric, demographic and reproductive variables and family history of 
cancer were gathered with an extensive questionnaire at entry into the cohort. A follow-up 
questionnaire mailed during 1993-2003 provides updated body weight information for all cohort 
members. Additional information on HRT, menopausal status, previous breast surgery and 
mammograms were obtained with the breast health questionnaire when the women enrolled in the 
mammographic density (NCC) study. 
 
2.2.2 Mammograms 
We retrieved the mammographic films from clinics located throughout the State of Hawaii. The 33 
different clinics and hospitals listed on the release forms were accredited according to the 
Mammography Quality Standards Act of 1992. Authorization forms signed by the study subjects 
were used to request these films.  
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2.2.3 Tissue from the Hawaii Tumor Registry 
The tissue analyzed in this study was provided by the Hawaii Tumor Registry (HTR), one of the 17 
state and regional central cancer registries of the Surveillance, Epidemiology, and End Results 
(SEER) program of the National Cancer Institute. The SEER program has provided data on cancer 
incidence and survival in the United States since 1973. As a population based cancer registry, it 
also aims to monitor trends and identify risk/protective factors for cancer development and offers 
huge research potential. The HTR collects data on patient demographics as well as clinical 
information including tumor site, histology, stage at diagnosis, first course of treatment, and follow-
up for vital status. To date it maintains information on nearly 130,000 cancer cases diagnosed in 
Hawaii (105). The foundation of one central repository that collects tissue specimens offers the 
advantage of a defined population basis, equal data quality standards and unbiased frequency 
measures of molecular markers. In addition, it greatly improves access to these specimens and 
important annotations, such as corresponding demographic, clinical and pathology information, 
concerning the patient. A Tissue advisory committee (TAC) provided scientific and ethical oversight 
and sets up policies for pathology specimens as well as guidelines for obtainment of tissue from 
the repository. The Tissue Discard Repository obtains tissue samples from pathology laboratories 
throughout the State since 1995. These tissues would have otherwise been discarded by medical 
facilities (after 5 -10 years) and therefore lost for research projects.  For those women diagnosed 
with cancer during the last 5-10 years, some specimens for this project were not part of the HTR at 
the time of analysis. The investigators took the extra effort and requested the tissue blocks directly 
from the hospitals where these women received their treatment. Briefly, to request tissue from the 
HTR, letters of intent with a study summary, approvals regarding research on human subjects (full 
institutional review board (IRB) review) and completed patient informed consent forms are needed. 
 
2.3 Assessment of breast tissue 
2.3.1 Selection of tissue 
The original histopathologic slides were evaluated with the help of Dr. Killeen, Clinical Pathologist 
and director of laboratories at Kapiolani Medical Center for Women and Children. He examikned 
the achieved tissue blocks from a certain tumor (in general up to 10 blocks from a given patient) 
and taking the laboratory reports as guidance, identified 1-2 blocks with sufficient tissue to sample. 
After this prescreening, the blocks were sectioned at 5 microns and between 1 to 10 hematoxylin 
and eosin (H&E) slides were prepared for each case. Each slide was examined microscopically 
with a magnification of 40 times, to identify morphologically representative regions from cancer and 
non-cancer areas. On the slide, showing the most representative malignant and benign tissue, 
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these areas were marked using different colors to make a distinction. Areas about 3 mm² to 6 mm² 
were circled in order to have enough tissue to choose from for the construction of TMAs and in the 
same time not to deplete the tumor for further research. Cancerous tissue was selected applying a 
black marker directly on the slide. In cases in which invasive and carcinoma in-situ co-existed, the 
areas showing invasive carcinoma were cirlced. For benign tissue a green color was used 
(figure 2). No distinction was made between specific areas of the tumor, such as center versus 
periphery or depth of invasion. The samples for Immunohistochemistry (IHC) were chosen based 
on the best quality and quantity of normal and malignant epithelium. The benign areas selected 
were preferably at far distance from the malignant parts to represent normal tissue for the study. 
The malignant tissue areas included mostly invasive tumors. Some cases (62 cases, 23%) 
however only showed ductal carcinoma in situ (DCIS). Both, benign and malignant areas were 
surrounded by different amounts of stromal and fatty tissue. Due to difficulty finding benign ducts in 
some of the blocks, more stromal tissue was marked for benign than for malignant cases. Even 
though the amounts of fatty tissue were preferrably kept as small as possible, some fatty tissue 
was included in the marked areas. The tissue microarrays only including fatty tissue were later 
excluded from the study. The marked H&E slides were sent back to the laboratory of the Cancer 
Research Center and aligned with the corresponding tissue blocks for the construction of the 
TMAs.  
 
   
A B C 
Fig. 2 Marking of benign (green) and malignant (black) areas of tissue for construction of                 
TMAs. Slide after marking (A), magnification of marked benign (B) and malignant (C) tissue.  
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2.3.2 Construction of tissue micro arrays 
Tissue Microarrays (TMAs) are a high-throughput and cost-effective method for the investigation of 
biomarkers in multiple tissue specimens simultaneously. TMAs are a collection of tissue cores 
arrayed into a single paraffin block which can be sectioned and mounted onto slides, producing up 
to 200 of nearly-identical sections. The technique of TMA preparation allows for the synchronized 
profiling of hundreds of specimens on a single microscopic slide, thus improving IHC efficiency. 
Suitable tissue can even be acquired from very small tumors. In our study, the tumor tissue blocks 
from the respective hospitals were used for the preparation of TMAs. From each of the formalin-
fixed, paraffin-embedded (FFPE) blocks, 4 cylindrical malignant and 4 cylindrical normal core 
biopsies were taken, using a specialized manual arraying instrument (Model MTA1, Beecher 
instruments, Sun Prairie, Wis). First, the original FFPE tissue blocks were aligned with the marked 
histological slides to identify the corresponding area of tissue on the (donor) paraffin block. This 
area was then precisely marked on the block to allow for an exact sample of tissue. Out of the 
region identified, cores were punched out from the donor block with a 0.6 mm diameter needle. 
These tissue cores (approximately 0.5 mm in diameter and 3-4 mm in height) were then embedded 
into a preformed hole of an empty (recipient) paraffin block. Each particular hole of the recipient 
block was punched out (with a needle of 0.7 mm in diameter) just before the construction of the 
core sample in order to not deform the block. From each block, 4 benign and 4 malignant cores 
were sampled, if sufficient tissue was available. We documented the location of individual 
specimens in the recipient block using computer template files. Each array in the series had its 
own numerical designation (1, 2, 3, and 4). The new TMA paraffin blocks were 37 x 25 x 10 mm in 
dimension. Spacing between the core centers was 0.7 to 1 mm. Using this array arrangement the 
newly formed tissue array block can contain up to 530 specimens due to the close alignment of 
tissue cores. For cases with insufficient tissue to obtain 4 malignant and/or 4 benign cores, fewer 
cores were taken, leaving the corresponding areas in the recipient block empty. Also included were 
samples from liver and spleen tissue as quality controls at the top and bottom of each TMA block 
as well as normal breast tissue controls interspersed throughout the array. These controls assist 
the user to track physical considerations of the TMA block or cut sections, such as edge effects or 
construction artifacts that might arise during processing of the slides. The TMA blocks were 
subsequently cycled between 37 and 4°C to form a more rigid structure in the paraffin, binding the 
tissue cores to the paraffin. These blocks were sectioned at 4 microns and each cut was mounted 
on a single slide. In general, 100 to 200 slides can be prepared from each tissue array block. 
These prepared sections were used for IHC analysis.  
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2.3.3 Immunohistochemistry (IHC) 
The TMAs were stained at the Wake Forest medical school, North Carolina in the lab of Dr. J. Mark 
Cline. The markers and characteristics of the antibodies are summarized in the following tables: 
 
Antibody Type Company Clone 
Ki-67  (monoclonal rabbit) Labvision NeoMarkers, Fremont, CA, USA SP6 
PCNA  (monoclonal mouse) Novocastra Labs, Newcastle-upon-Tyne, UK PC10 
ERα  (monoclonal mouse) Novocastra Labs, Newcastle-upon-Tyne, UK 6F11 
ERß  (monoclonal mouse) Novocastra Labs, Newcastle-upon-Tyne, UK EMR02 
PR (monoclonal mouse) Novocastra Labs, Newcastle-upon-Tyne, UK 1A6 
HER2/neu  (monoclonal mouse) DAKO Corporation, Carpinteria, CA, USA  
Table 1  Primary Antibodies used for staining of epithelial tissue 
 
 
Antibody Type Company Catalog # 
MMP1  (monoclonal rabbit) Epitomics, Inc., Burlingame, CA, USA 1906-1 
MMP3  (monoclonal rabbit) Epitomics, Inc., Burlingame, CA, USA 1908-1 
MMP9 (monoclonal rabbit) Epitomics, Inc., Burlingame, CA, USA 1939-1 
MMP12  (monoclonal rabbit) Epitomics, Inc., Burlingame, CA, USA 1906-1 
TIMP3 (polyclonal rabbit) Cell Applications, Inc., San Diego, Ca, USA CA0577 
Table 2  Primary Antibodies used for staining of stromal tissue 
 
Staining procedures of the TMA slides were performed on the fixed, paraffin-embedded tissues. 
The basic staining procedure uses an avidin-biotin-alkaline phosphatase method, modified for 
antigen retrieval from paraffin-embedded tissue using the procedure of Shi et al. (108). Briefly, 
slides were deparaffinized through Xylene and alcohols to citrate buffer (pH 6.0), heat-treated for 
antigen recovery and exposed with the primary antibodies overnight at 40C. Subsequently, tissue 
sections were exposed to biotin-streptavidin link and labeling antibodies (Biogenex, San Ramon, 
CA, USA), and finally visualized using the chromogen-substrate Vector Red (Vector Laboratories, 
Burlingame, CA, USA). Sections were counterstained with Mayer's hematoxylin, dehydrated, 
cleared through p-Xylene and coverslipped. With each staining batch, positive and negative 
controls were prepared for each marker.  
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2.3.4 Image Analysis 
Slides that were stained for epithelial markers (ER α and β, PR, Ki-67, PCNA and HER2/neu) were 
measured at the Wake Forest medical school with image analysis software for 
immunohistochemical stains (Image Pro Plus Software, Media Cybernetics). I evaluated the TMAs 
stained for stromal markers (MMPs and TIMP) at the Cancer Research Center of Hawaii. A trained 
pathologist (JMC) reviewed all specimens after staining to confirm their benign or malignant 
epithelial tissue content. If variables were discrepant, they were recoded according to the new 
reading. 
For epithelial markers, pictures of each TMA were taken with an Infinity 3 Digital Video Camera 
(Lumenera Scientific) at Wake Forest medical school (figure 3). Slides were placed under the 
10 X objective of a microscope which then displayed the image on the computer screen in the 
image analysis program. The evaluation of stains was performed on a snapshot taken from the 
screen. Results were recorded as continuous variables. The area of all nuclei (A) was measured by 
a color selection corresponding to hematoxylin, whereas the area of positively stained nuclei (B) 
was measured by a color selection corresponding to the Vector Red chromogen. For the nuclear 
stains used in this study the percentage of staining was expressed as B/A x 100. For subjects with 
more than one measurement available, results were subsequently averaged.  
In the second part of the study, the staining for stromal markers (MMPs), slides were scanned from 
Aperio Scanning Services (Vista, CA) and digital images for each slide were evaluated for analysis 
(figure 4).  
 
 
Fig.  3 Representative micrographs of the respective stains in benign (top row) and 
malignant (bottom row) tissue. 
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Fig. 4  Examples of staining results for stromal markers in epithelial (A-C) and stromal (D-E) 
tissue: no (A), medium (B) and strong stain (C) and no stain (D) versus any stain (E). 
 
2.4. Breast density analysis 
Mammograms were evaluated by a computer-assisted density assessment using the Cumulus 108 
software, a program designed to operate under Windows to display digitized mammograms and 
allow thresholding operations. First, each film was scanned with a Kodak LS 85 Film Digitizer 
(absorbance range, 0.001-4.1; Eastman Kodak Company, Rochester, New York) at a resolution of 
98 pixels per inch (pixel size equal to 260μm). For density assessment, the 8-bit images are 
displayed in 256 shades of gray. Originally, several mammograms were available for each patient. 
If possible, we only included films taken before the date of diagnosis of breast cancer. Otherwise, 
the mammogram of the contralateral breast was used in our study. In order to analyze 
histopathologic features in association with mammographic density, we included the mammogram 
taken closest to the diagnosis of breast cancer and, therefore, closest to collection of our tissue 
samples. In our analysis, only the cranio-caudal views of mammograms are studied. For 
participants, mammograms were taken 2.4 ± 2.6 years after entry into the cohort and 2.7 ± 2 years 
after completion of the baseline questionnaire. We randomly ordered all images to be read into 
batches of 50 mammograms each (except for the last batch, which included 30 films). The reader 
was blinded as to identity and year of the films and performed computer-assisted density readings. 
For assessment of intraobserver agreement, a separate batch with randomly chosen images of the 
other 9 batches was assessed in a separate session. An example for the computer-assised density 
measurement is shown in figure 5. We first set a threshold for each image, to determine the 
outside margin of the breast. This threshold, shown by a red line, separates the image of the 
breast from the black background. To establish the dorsal margin of the breast and to cut off the 
Musculus pectoralis a line was subsequently drawn from top to bottom of the breast image. The 
computer calculates the number of pixels in the digitized image that constitute the total area of the 
breast. To measure the dense area, a second threshold is set, which surrounds the lightest areas 
of the breast image with a green line, indicating radiodense tissue. Percent breast density is then 
computed by dividing the dense area by the total area and multiplying the result with 100. To 
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convert the pixels into square centimeters we used a factor of 0.000676. Given the high correlation 
between readings from the right and the left breast, mean values were used for the analysis when 
both mammograms were available. 137 (48.4%) of the values are based on the readings of one 
side only. For the remaining 146 participants (51.6%) we calculated mean values form both 
readings.   
 
 
 
 
 
 
 
 
Red = total breast area 
Green =  dense areas 
Ratio = percent density 
 
Fig. 5  Computer assisted density measurement (2) 
 
2.5 Statistical Analysis 
Data management and statistical analysis were performed using the SAS statistical software 
package 9.1 (SAS Institute Inc., Cary, NC). No names or other identifying information was part of 
the analytical database. Histopathologic results were added to the database of nutritional, 
demographic, and medical information obtained from the food frequency questionnaire (FFQ) using 
the study identification number as a link. We examined the data for completeness, outliers and 
possible coding errors. All continuous variables were inspected for skewness of their distribution. 
For those outcome variables deviating form normal distribution, we applied appropriate 
transformation or created categorical variables.  
 
 
22 
 
2.5.1 Variables 
For the assessment of breast density, the variables percent density, dense area of the breast and 
total area of the breast were included in our analysis as continuous variables. Dense area was 
square root transformed for analysis to normalize the distribution.  For ease of interpretation, back-
transformed values are presented in the tables. 
For epithelial markers, we computed means for percent staining of all available cores for each 
subject, separately for benign and malignant tissue. In benign tissues, distributions of all six 
epithelial markers were skewed with strong left tails. The interquartile ranges for benign tissue 
were 0.0-8.1% (ERα), 0.0-13.8% (ERß), 0.0 – 1.5% (PR), 0.0-14.5% (HER2/neu) , 0.0-0.6% Ki-67) 
and 0.8-16.2% (PCNA), respectively. Consequently, staining results for ERα, ERß and HER2/neu 
and PCNA were divided into two categories; negative staining (less than 10% of cells stained) and 
positive staining (at least 10% of cells stained). PR and Ki-67 were strongly left skewed; in benign 
tissue only 4 and 13 women respectively, had positive (≥10%) staining. Thus we dichotomized 
these results into the groups no vs. any epithelial staining. In malignant tissue the individual 
interquartile ranges were 3.8-44.1% (ERα), 0.0-11.8% (ERß), 0.0-7.4% (PR), 3.7-40.1% 
(HER2/neu), 0.2-2.5% (Ki-67) and 20.9-55.0% (PCNA). Therefore, more detailed categories were 
created for these markers. We categorized into negative (no cells stained positive), weak staining 
(<10% of cells stained positive) and stronger staining (≥10% of cells stained positive) for ERα and 
ERβ; into no (0-1%), weak (1-10%) and strong staining (>10%) for HER2/neu and no (0-1%), weak 
(1-20%) and strong staining (>20%) for PCNA. We kept the categories no vs. any epithelial 
staining for PR and Ki-67 staining results.    
Measurement results of the MMP stains in epithelial tissue were categorized as no, weak or strong 
staining, whereas staining of stromal tissue was dichotomized into no vs. any stain. A weight 
variable for every marker, reflecting the amount of benign and malignant samples (1 to 4) was 
calculated for each participant. For each subject, the benign and malignant core with the strongest 
level of staining was selected for the analysis. Only women with at least one measurement per 
marker and category (epithelial vs. stromal) were included in our analysis.  
For the ethnicity variable, the ethnic background for both parents was reported on the 
questionnaires. We classified persons with more than one ancestry into a single ethnic category, 
giving first priority to Hawaiian followed by Japanese, then Caucasian, and finally Other (105). 
Ethnicity was categorized into Caucasian, Japanese, Hawaiian and others. Due to small numbers 
(Hawaiian n=31, others n=26) stratified analyses on density and markers were only performed for 
Japanese (n=121) and Caucasian (n=100) women separately. 
In our analysis we only included the HRT variable for the mammogram, which was taken closest to 
the date of diagnosis of breast cancer. For women with missing HRT type information, we assigned 
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a type of HRT based on their hysterectomy status (109). For those who underwent hysterectomy 
we assigned Estrogen only therapy, otherwise combined HRT was imputed.  
For menopausal status a similar approach was used. If we had the information that a woman 
underwent menopause, but were uncertain about the menopausal status of the specific year, we 
assigned a perimenopausal variable. Because of the small frequency count of women in this group 
(10 women, 0.35%), they were included in the premenopausal group in our analysis.  
The body mass index (BMI) (weight (kg)/height in (m)²), was included as a continuous variable. 
However, for analysis stratified by BMI, we created four categories: <20, 20-25, 25-30 
and >30 kg/m².  
 
2.5.2 Analysis 
To examine differences between the study population of our study and the original NCC study we 
employed χ² analysis for categorical variables and t-tests for continuous variables.  For all epithelial 
markers, intraclass correlation coefficients (ICCs) were computed for benign and malignant tissue 
to assess marker agreement between the four samples per subject. Distributions of all staining 
results were analysed for the overall population and ethnic subgroups. Agreement between 
markers in benign and malignant tissue of each participant and correlation between the different 
markers were computed with χ²-and Spearman correlation coefficients, respectively.  
We applied general linear models to determine the relation between markers and mammographic 
densities while adjusting for covariates that are known to be related to breast cancer risk. Potential 
confounders included age at mammogram, BMI as a continuous variable, ethnicity (Hawaiian, 
Japanese, Caucasian and Other), parity (0-1 children, 2-3 children and > 3 children), age at first 
live birth (< 21 years, 21-30 years, or > 30 years, or no children), age at menarche (< 13 years, 13-
14 years, or > 14 years), menopausal status, HRT use at mammogram (no use, estrogen only, 
combined estrogen and progesterone), family history of breast cancer in a first degree relative 
(yes, no) and tumor stage (in-situ, localized, regional, unknown). All analyses were conducted 
separately for malignant and benign tissue and stratified by ethnicity.  
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3. Results 
3.1 Baseline characteristics of study participants 
For this analysis we recruited 283 breast cancer cases with primarily Caucasian (35.3%) and 
Japanese (42.8%) ancestry. Also included were 12.7% Hawaiians and 9.2% women of other 
ancestries. The mean age at the time of the analyzed mammogram was 60.2 ± 8.6 years. This 
relatively old mean age is partly due to the age limit of 45-75 years for entry into the MEC on which 
this population was based.  More than two-thirds of the participants were postmenopausal (79.5%), 
the majority of whom did not use HRT (44.9%). The other 30.7% reported use of HRT with only 
estrogen, whereas 24.4% of postmenopausal women reported combined HRT treatment. Nearly all 
women in our study had early-stage disease consisting of either carcinoma in situ (21.9%) or 
localized invasive carcinoma (60.8%). The characteristics of the 283 participants included in this 
study compared with those of the NCC study are presented in table 3. Comparison of the women 
included in the analysis with the excluded cases showed only small differences. Japanese cases 
made up 51% of the excluded cases, Caucasians 26% and Hawaiians 14%, representing a similar 
distribution to the included women. The included cases were 3.2 years younger (p<0.0001) and 
more likely to be postmenopausal at the time the mammogram was taken (p= 0.0002). They also 
showed a higher prevalence of use of oral contraceptives in the past (50.2% vs. 37.0%; p<0.0004). 
Mean percent breast density was slightly higher in participants (38.9% vs. 35.4%; p=0.053). There 
were no significant differences in BMI (kg/m²), family history of breast cancer, age at menarche, 
age at fist life birth, parity, HRT, use or class of HRT used. These findings indicate a representative 
sample of the population.  
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Table 3  Characteristics of women recruited for the NCC-study and for the TMA study 
Variable NCC-Study Patho-Study p-value° 
Sample Size (No.) 607 283   
Ethnicity   0.09 
Caucasian 185 (30.5%) 100 (35.3%)  
Hawaiian 80 (13.2%)  36 (12.7 %)  
Japanese 287 (47.3%) 121 (42.8%)  
Other 55 (9.1%) 26 (9.2%)  
Age at mammogram* 63.7 ± 8.1 60.2 ± 8.6 < 0.0001 
Body mass index (kg/m²)* 25.3 ± 5.6 24.7 ± 4.5 0.19 
FH of breast cancer¹ 103 (17.0%) 42 (14.8%) 0.19 
Age at menarche   0.72 
< 13 years 334 (55.0%) 159 (56.2%)  
13-14 years 218 (35.9%) 97 (34.3%)  
>14 years 55 (9.1%) 27 (9.5%)  
Number of children   0.35 
0-1 166 (27.4%) 85 (30.0%)  
2 to 3 314 (51.7%)  143 (50.5%)  
>3 127 (20.9%) 55 (19.4%)  
Age at first live birth   0.27 
<21 years 80 (13.2%) 41 (17.7%)  
21-30 years 377 (62.0%) 170 (14.5%)  
>30 years 56 (9.2%) 22 (60.1%)  
N/A 94 (15.5%) 50 (7.8%)  
Oral contraceptive (OC) use  0.0004 
Never 341 (56.4%) 137 (48.8%)  
Ever 264 (43.6%) 144 (51.2%)  
HRT use at mammogram:   0.19 
No use 264 (43.5%) 127 (44.9%)  
Estrogen only 174 (28.7%) 87 (30.7%)  
Combined HRT 169 (27.8%) 69 (24.4%)  
Breast density in percent* 33.5 ± 23.0 37.5 ± 23.5 0.035 
Menopausal Status   0.0002 
Postmenopausal 517 (85.2%) 225 (79.5%)  
Premenopausal 90 (14.8%) 58 (20.5%)  
Tumor Stage   0.30 
In-situ 124 (20.4%) 62 (21.9%)  
Localized 368 (60.6%) 172 (60.8%)  
Reginal 96 (15.8%) 38 (13.4%)  
Unknown 18 (3.0%) 11 (3.9%)    
 
* Mean values are given 
¹ Diagnosis of breast cancer in any first-degree relative 
° p-values from χ² - and Student's T test comparing cases included in the TMA study and those excluded 
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3.2 Quality of mammographic measurements 
For assessment of intraobserver agreement (JSS), an individual batch with 45 randomly chosen 
images of the other 9 batches was assessed in a separate session. Based on these duplicate 
readings, the reproducibility of the density measurement was high, showing an intrareader 
correlation coefficient for percent density of 0.95 and 0.93 for dense area.  
The mammograms from the NCC study participants have also been assessed by only one reader 
(G.M.); the intraclass correlation coefficients derived from duplicate readings were 0.96 for the size 
of the dense area and 0.97 for percent density. 
Comparison of measurements from both observers showed an interreader correlation coefficient of 
0.87. To evaluate agreement more precisely we created categories for percent breast density. 
Measurements were divided into the categories low (<10), medium (10 - 24.9), medium high (25 - 
49.9) and high (≥50). Comparison of both readings can be seen in figures 6.1 and 6.2. Computing 
kappa statistics, we found a moderate interreader agreement (κ=0.49). When comparing only two 
categories of density (high versus low), comprised of values higher or lower than the median of the 
respective evaluation, we calculated a kappa value of 0.65 indicating substantial agreement 
between readers. To ensure consistency of results with prior published studies, we only used 
readings by G.M. in our analyses.  
 
 
 
  
 Fig. 6.1  Interreader agreement of precent density measurements 
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 Fig 6.2  Interreader agreement of categorized precent density measurements  
 
3.3 Association between breast density and risk factors 
The percent breast density in our study population (n=283) ranged from 0.5% to 89.6% with a 
mean of 37.5% (±23.5). Mean dense area was 37.8 cm² (±25.36) with a range from 1.4 to 
134.9 cm². The mean total breast area as measured on the mammograms was 116.0 cm². 
Conducting analysis of variance we found percent breast density to differ significantly by age 
(p=0.001), menopausal status (p=0.001), HRT (p=0.002), BMI (p<0.0001), parity (p=0.002) and 
age at first live birth (p=0.007) (table 4). Separate analyses stratified by ethnicity are shown in table 
5. Mean percent density adjusted for age was lowest in women of Hawaiian and Caucasian 
ancestry, i.e. 30.2% and 36.0% respectively.  Japanese had a mean density of 39.8%, whereas 
women of other ancestries had the highest density measurements with a mean of 42.7%. 
However, these differences were non significant (p=0.07). After adjustment for other known 
confounders only small differences in percent density were observed in the different ethnic 
categories. Mean percent density was lowest in Caucasian (35.4%) compared to the other 
subgroups, i.e. 38.9% (Hawaiian), 39.6% (Japanese) and 39.6% (other ancestries). The mean age 
when the mammogram was taken differed by group (p=0.04): Caucasian 60.0 years, Hawaiian 
57.5 years, Japanese 60.0 years and for the group „Others‟ 55.0 years. Also BMI differed 
significantly by ethnic group (p=0.0001). Hawaiians had the highest mean BMI with 28.03 kg/m² 
whereas the mean BMI for others was lowest with 23.62 kg/m².  
The difference of a lesser density by age in the overall population remained significant (p=0.0005) 
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after full adjustment for all confounders. Density was also significantly higher in premenopausal 
(48.6% [42.7-54.4]) than in postmenopausal women (34.7% [31.7-38.5]) (p<0.0001). BMI was quite 
similar in pre- and postmenopausal participants (p=0.79). Premenopausal women had a mean BMI 
of 24.65 kg/m²; postmenopausal women had a mean BMI of 24.83 kg/m². Among postmenopausal 
women breast density differed significantly by type of HRT, with highest density percentages in the 
combined HRT group (p=0.002). Mean breast density was 30.7% in 127 women not taking HRT, 
32.2% in 87 women taking estrogen alone and 42.9% in 69 women taking combined HRT with 
progestin and estrogen. 
 
 Table 4  Association of breast density with breast cancer risk factors 
  n Percent density p-value ¹ 
    Mean % (95%CI)   
Overall 283 37.5 (34.7 - 40.2)  
Menopausal status     
Premenopausal 58 48.6 (42.7 - 54.5)  
Postmenopausal 225 34.6 (31.6 - 37.6) 0.001 
HRT use     
No HRT 127 30.6 (25.7 - 35.5)  
Estrogen only 87 32.3 (27.3 - 37.2)  
Estrogen + Progest. 69 43.0 (37.3 - 48.6) 0.002 
BMI kg/m²     
< 20 33 52.8 (45.3 - 60.3)  
20-25 137 41.5 (37.8 - 45.2)  
25-30 81 30.2 (25.4 - 35.0)  
>30 32 22.9 (15.2 - 30.6) < 0.0001 
Number of children     
0-1 85 41.9 (37.0 - 46.9)  
2 to 3 143 38.6 (34.7 - 42.3)  
>3 55 27.8 (21.6 - 33.9) 0.002 
Age at first live birth     
<21 years 50 46.3 (39.9 - 52.7)  
21-30 years 41 27.4 (20.3 - 34.4)  
>30 years 170 36.4 (33.0 - 40.0)  
N/A 22 44.3 (34.7 - 54.0) 0.007 
 
¹ p-value for general linear models (percent density) 
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 Table 5  Mean percent density in different ethnic groups 
  Percent Densityª Dense Areaª BMI
b
 Age
c
 
Ethnicity n (95%CI) (95%CI)   
Caucasian 100 35.4 40.2 24.5 61.4 
    (31.2 - 39.5) (35.3 - 45.2)  (23.54-25.46) (59.7-63.1) 
Hawaiian 36 38.9 42.1 28.03 57.8 
  (31.6 - 46.2)  (33.3 - 50.8) (26.12-29.93) (54.7-60.9) 
Japanese 121 39.6 35.7 24.31 60.6 
  (35.8 - 43.4) (31.2 - 40.3) (23.72-24.91) (59.1-62.1) 
Other 26 39.3 38.5 23.62 57.2 
  (31.0 - 47.7) (28.5 - 48.5) (21.81-25.36) (53.8-60.5) 
 
ª Adjusted for age at mammogram, body mass index, menopausal status, age at menarche,  
  HRT use at time of mammogram, age at first life birth, parity and family history of breast cancer 
b 
Body mass index; weight (kg)/height in (m)
2
        
c
 Age at time of mammogram         
 
 
3.4 Number of cores on TMA 
For 4 of the 283 recruited subjects, not enough tissue was available on the selected tissue blocks 
for placement on TMAs. We therefore only constructed TMA blocks for 279 women. Out of the 
2232 possible TMAs (four malignant and four benign samples for 279 women), 459 cores (20.6%) 
could not be placed due to insufficient tissue on the respective block. Of these, 29% (134 cores) 
were of malignant tissue and 71% (325 cores) of benign samples. Overall 1773 (79.4%) tissue 
cores were successfully placed on the respective blocks. During staining for stromal markers, 
about 4 – 8% of samples fell off the slides. The numbers were quite similar throughout the 
particular stromal markers.  
During staining for epithelial markers, about 7-9% TMAs fell off and numbers were also quite 
similar across individual markers. For all the markers collectively, about twice as many benign vs. 
malignant samples were missing after staining.  
On average, 3.1 malignant tissue samples and 1.7 benign samples were available per women for 
the epithelial markers. For stromal markers on the other hand, 3.5 malignant and 2.9 benign TMAs 
were available on average per women. For stromal markers up to 3% of cores could not be 
properly evaluated due to artifacts (vascular stain, fluid in duct, stained red blood cells, among 
others). About 11.6-13.7% of cores had less than 25% of tissue present and were, therefore, not 
evaluated. For subsequent analyses, we used data sets including only those women who had at 
least one measureable stain for the respective markers. For epithelial markers, 268 women (159 
women with only benign samples and 253 women with only malignant measurements) were 
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included. In our stromal marker datasets we had 277 women, 259 women with at least one benign 
and 274 with at least one malignant measurement (figures 7.1 and 7.2).  
 
 
 
Fig. 7.1  Loss of subjects and tissue throughout recruitment and TMA construction 
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Fig. 7.2  Cores placed on TMAs 
 
 
3.5 Descriptive analysis of markers 
3.5.1 Hormonal and proliferation markers 
To assess the agreement per subject, ICCs were computed for all epithelial markers. Across 
malignant samples, ICCs varied between 0.45 and 0.74 depending on the specific marker, 
whereas ICCs for benign tissue were 0.20-0.42 indicating fair and moderate to substantial 
agreement. Distributions of all six epithelial markers were skewed with strong left tails (figure 8.1). 
A substantial proportion of the benign samples were in the low or no staining categories. The 
percentages were 78% (ERα), 70% (ERß), 49% (PR), 67% (HER2/neu), 42% (PCNA) and 60% 
(Ki-67). In malignant specimens low or no staining was considerably less frequent for all epithelial 
markers except for ERβ (70% of TMAs were in the no or < 10% staining categories). Percentages 
for other markers were 33% (ERα), 23.4% (HER2/neu) and 28% (PR). The proliferation markers 
were negative or low in 9% (PCNA) and 11.9% (Ki-67) of malignant specimens (see figure 8.2). A 
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similar proportion of Japanese and Caucasian women were in the highest staining category for all 
markers. None of the differences were statistically significant. The samples size was too small to 
examine other ethnic groups.  
There was substantial, statistically significant agreement for the markers ERα (p=0.002), ERß 
(p<0.0001) and PR (p=0.03) in benign and malignant specimens of the same subjects. The 
proliferation markers Ki-67 and PCNA as well as HER2/neu did not correlate (p=0.30 and p=0.20, 
and p=0.13 respectively). In benign tissue, based on Spearman correlation coefficients, all 
epithelial histopathologic markers were significantly positively correlated with each other except for 
ERβ and PR. There was an especially strong correlation between ERα and PCNA 
(ρ=0.64;p<0.0001) as well as Ki-67 (ρ=0.31 p<0.0001) and HER2/neu (ρ=0.38, p=0.0001). These 
associations were also significant in malignant tissue, but not as strongly. ERα was positively 
associated to PCNA (ρ=0.47, p<0.0001), but not significantly correlated to Ki-67 expression, 
whereas ERβ was positively correlated with Ki-67 (ρ=0.33; p<0.0001).  
 
 
Fig. 8.1  Distribution of positive staining results in benign tissue 
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Fig. 8.2  Distribution of positive staining results in malignant tissue 
3.5.2 Stromal markers 
The percentages of positive stained cells for the respective stromal markers and tissue origin are 
shown in figures 9.1 and 9.2. Of all subjects in the stromal marker subgroup only 2% of benign and 
8% of malignant epithelial specimens stained positive for MMP3; No stromal samples showed 
positive staining. For MMP9, only 5% stained positive in benign and 18% in malignant epithelium. 
In stromal tissue samples, 5% and 1% stained positive in malignant and benign tissue, 
respectively. Due to this lack of staining we did not include MMP3 and MMP9 in further analyses.  
For MMP1 and MMP12, epithelial as well as stromal marker expressions were more likely to be 
higher in malignant than in benign tissue. In stromal tissue, the proportion of positive stained cells 
was 28% (malignant) and 20% (benign) for MMP1 (p<0.0001) and 38% (malignant) and 10% 
(benign) for MMP12 (p=0.001). In epithelium, the percentages of strongly positive stained cells 
were 52% and 34% for MMP1 and 75% and 44% for MMP12 for malignant and benign tissue, 
respectively. 
In epithelium, expression of TIMP3 was higher in malignant (16% strongly positive) than benign 
(8%) tissue (p<0.0001), whereas stromal tissue expression was higher in benign (33%) than 
malignant (19%) samples (p<0.0001). We observed no significant difference in staining between 
Japanese and Caucasian except for MMP12 in malignant tissue; the proportion stained was higher 
in Japanese than Caucasian women both in stromal (p=0.056) and epithelial tissue (p=0.03).  
 
 
34 
 
 
  Fig. 9.1  Percent of positive staining results for MMPs in epithelial tissue  
 
 
 
Fig. 9.2  Percent of positive staining results for MMPs in stromal tissue  
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3.6 Association of density with histopathologic markers 
The association between breast density as a continuous measure and categories of 
histopathologic markers was analyzed using general linear models. We adjusted for covariates that 
are known, as mentioned above, to be associated with breast density.  
3.6.1 Hormonal and proliferative markers  
Overall, only small differences in breast density were seen between staining categories of several 
markers (figures 10.1 – 10.3). Most of our findings were not statistically significant (tables 6 and 7). 
We observed consistently higher mammographic density for women with PR expression across the 
two major ethnic groups (all women: 3.4%; Caucasian: 5.8%; Japanese: 3.5%). These findings 
were similar in malignant samples of all women. For women with stronger ERß staining, percent 
density was higher in the overall population and in Caucasians (2.4% and 11.6%) but not in 
Japanese. The difference among Caucasian women was statistically significant (p=0.05). There 
was no consistency in malignant samples. Furthermore, no consistent associations of percent 
density with ERα and HER2/neu were observed. Among Caucasian women, percent breast density 
was significantly less extensive in women with low than high staining for ERα (39.8% and 23.9% 
respectively, p=0.04). However, Japanese women showed an inverse correlation which was also 
observed for staining in malignant samples; Mean percent density was 31.9% (no stain), 43.5% 
(weak stain) and 38.0% (strong stain, p=0.05).  
Percent density was slightly higher in women with Ki-67 staining both in the overall population 
(3.4%) as well as in ethnic groups (Caucasians: 3.8% and Japanese 4.4%). Only 12% of malignant 
samples were in the low staining group, and percent density did not differ significantly between low 
and hight staining for Ki-67.  
Women with positive staining for PCNA showed slightly higher percent density. This finding was 
consistent among the overall study group and Japanese but not among Caucasians. In malignant 
samples, breast density was lower in women with higher PCNA staining.  
Restricting the analyses to postmenopausal women did not substantially change the results of the 
overall analyses of benign samples for ERα, HER2/neu, and the proliferative markers, whereas the 
associations of benign ERβ and PR staining with mammographic density became somewhat 
stronger. The respective mean percent densities for ERβ were 26.4% vs. 32.0% (p=0.22) and 
25.3% vs. 30.8% (p=0.18) for PR (data not shown).  
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Fig. 10.1 Density and epithelial markers in benign tissue of all women°  
 
Fig. 10.2 Density and epithelial markers in benign tissue of Caucasian women° 
 
Fig. 10.3 Density and epithelial markers in benign tissue of Japanese women° 
° Categories for staining and numbers of subjects per group are shown in table 6. 
* adjusted for age at mammogram, BMI, menopausal status, age at menarche,   HRT use at time of mammogram, age at       
   first life birth, parity and family history of breast cancer 
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Table 7  Breast density and marker expression in malignant sampels 
Marker  Staining category p-valueª 
  1 2 3  
ERα Percent density 31.9 43.5 38.0 0.05 
 Number 29 55 168  
ERβ Percent density 38.0 41.4 35.5 0.17 
 Number 68 110 73  
HER2/neu Percent density 35.5 40.0 37.7 0.60 
 Number 25 57 194  
PCNA Percent density 53.1 39.6 35.8 0.24 
  Number 20 59 196   
PR Percent density 37.1 39.7   0.39 
 Number 70 183   
Ki-67 Percent density 40.7 38.4  0.58 
  Number 30 221     
 
 
Staining categories: ERα and Erß: 1 (negative), 2 (<10%); 3 (≥ 10%)  
PR and Ki-67: 1 (no staining); 2 (any staining); 
PCNA: 1 (0-1%); 2 (1-20-%); 3 (>20%); HER2/neu: 1 (0-1%); 2 (1-10%); 3 (>10%) 
ªp-values given for glm-analysis of differnce in percent breast density by staining group; 
adjusted for known confounders as mentioned above 
 
 
 
Table 6  Numbers of subjects per group for analysis of benign samples 
 All women (n=159) Caucasian (n=49) Japanese (n=70) 
Marker Staining   Staining   Staining   
  low high p-valueª low high p-valueª low high p-valueª 
ERα 122 35 0.75 38 11 0.04 53 16 0.39 
ERß 110 47 0.49 36 13 0.05 47 21 0.85 
HER2/neu 104 52 0.82 34 15 0.38 45 23 0.57 
PCNA 95 63 0.50 28 20 0.91 42 28 0.52 
PR* 77 81 0.28 23 25 0.30 35 35 0.57 
Ki-67* 65 90 0.32 16 32 0.53 31 39 0.46 
 
ª p-values given for glm-analysis of differnce in percent breast density by staining group; adjusted    
  for known confounders as mentioned above 
* Staining categories for PR, Ki-67: low (no staining); high (any staining); for ERα, ERß,  
   HER2/neu and PCNA: low (<10% staining), high (≥10% staining).  
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3.6.2 Stromal markers 
There was no statistically significant association of MMP1, MMP12, and TIMP3 with breast density 
in the entire study population (figure 11.1). After stratification by ethnicity, we noted several 
discrepant associations (figures 11.2 and 11.3). In Japanese women, density was inversely 
associated with MMP1 expression (31.5% for any stain vs. 41.3% for no stain in malignant stromal 
tissue; p=0.04). The same trend, though not significant, was observed in epithelium. In contrast, 
percent density was higher in Caucasian women with more extensive MMP1 expression; the 
respective values for malignant stromal tissue were 40.7% vs. 32.1% (p=0.12).  
Although not statistically significant, mean percent density was lower with more extensive TIMP3 
expression both in stromal and epithelial tissue. In stromal tissue, mean density was 40.0 vs. 36.9 
(p=0.28) for no vs. any stain in benign tissue; the respective values for malignant tissue were 36.0 
vs. 35.7 (p=0.73). In benign epithelial tissue, mean density was 43.9% vs. 31.5% for no vs. strong 
stain (p=0.10); the respective values for malignant epithelial tissue were 39.2% vs. 31.9% (p=0.18). 
With one exception (malignant stromal tissue of Caucasians), the inverse association was 
consistent across ethnic groups. 
 
 
Fig. 11.1 Density and MMPs in epithelial and stromal tissue of all women° 
  
° Categories for staining and numbers of subjects per group are shown in table 6. 
* adjusted for age at mammogram, BMI, menopausal status, age at menarche,   HRT use at time of mammogram, age at     
   first life birth, parity and family history of breast cancer 
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Fig. 11.2  Density and MMPs in epithelial and stromal tissue of Caucasian women° 
  
     
Fig. 11.3  Density and MMPs in epithelial and stromal tissue of Japanese women° 
  
° Categories for staining and numbers of subjects per group are shown in table 6. 
* adjusted for age at mammogram, BMI, menopausal status, age at menarche,   HRT use at time of mammogram, age at       
   first life birth, parity and family history of breast cancer 
 
 
Table 8.1  Numbers of subjects per group for analysis of epithelial tissue 
  All women (n=277) Caucasian (n=100)   Japanese (n=121) 
Marker Tissue Staining   Staining   Staining   
  1 2 3 p-value 1 2 3 p-value 1 2 3 p-value 
MMP1 mal  30 89 130 0.85 8 31 43 0.19 18 39 53 0.80 
 ben  28 72 53 0.82 7 22 17 0.38 16 37 20 0.87 
MMP12 mal  15 49 192 0.50 10 21 55 0.70 4 20 87 0.90 
 ben  28 61 69 0.90 6 17 24 0.81 17 30 26 0.60 
TIMP3 mal  96 118 40 0.18 41 32 12 0.47 37 54 22 0.29 
  ben  77 57 12 0.09 22 20 6 0.42 29 23 3 0.22 
Staining categories: 1 (no stain); 2 (weak stain); 3 (strong stain); p-values given for glm-analysis of differnce in  
percent breast density by staining group; adjusted for known confounders as mentioned above 
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Table 8.2  Numbers of subjects per group for analysis of stromal tissue 
   All women (n=277) Caucasian (n=100) 
  
Japanese (n=121) 
Marker Tissue 
no 
stain 
any 
stain p-value 
no 
stain 
any 
stain p-value 
no 
stain 
any 
stain p-value 
MMP1 mal  192 75 0.71 69 24 0.11 83 31 0.04 
 ben  189 49 0.37 67 15 0.34 82 22 0.20 
MMP12 mal  165 99 0.45 66 26 0.62 66 46 0.40 
 ben  197 23 0.49 66 10 0.58 84 9 0.88 
TIMP3 mal  218 51 0.73 73 20 0.60 94 23 0.48 
  ben  158 78 0.27 53 29 0.50 72 30 0.26 
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4. Discussion 
Breast density, the radiographic appearance of the female breast, is one of the strongest risk 
factors for breast cancer. Although a vast body of literature describes a positive association 
between breast density and breast cancer, reporting risk estimates up to 6.0 (3, 9), the biological 
mechanisms underlying this association are largely unknown. Density has inconsistently been 
reported to be associated to histopathologic changes, such as proliferative lesions of epithelium, 
stroma or both (88, 89). Several other breast cancer risk factors, especially those connected to an 
increase in estrogen exposure, have as well been shown to increase the extend of 
mammographically dense tissue.   
Since stroma compromises most of the radiographic dense tissue, alterations in the extra-cellular 
matrix might also be connected, in a causal matter to the mechanisms underlying the associated 
breast cancer risk. MMPs play a crucial role in breast carcinogenesis and have not yet been 
analyzed in their relation to breast density.  
In this study, we recruited 283 breast cancer cases of mainly Caucasian and Japanese ancestry 
and examined breast density and its association with hormonal (ERα, ERβ, PR) proliferative (Ki-67, 
PCNA, HER2/neu) and stromal markers (MMP1,3, 9 and 12 and TIMP3). 
In TMAs of benign and malignant breast tissue samples, we did not observed any significant 
association in the overall study population. The topic of this investigation is of importance because 
the histological correlates of mammographic density are very poorly understood, and yet, 
mammographic density is widely used as a biomarker for breast cancer risk and considered an 
important tool for breast cancer risk assessment and management. 
 
4.1 Major findings and interpretations 
4.1.1 Density and hormonal and proliferative markers 
We found all hormonal (ERα, ERβ and PR) and proliferative markers (Ki-67, PCNA, and 
HER2/neu) to be much more frequently expressed in malignant than in benign tissue. For all these 
markers, findings did not differ significantly by ethnicity. In benign tissue ERα was significantly 
correlated to proliferative markers.  
These results agree with the general understanding of higher expression in malignant samples. 
Especially markers indicating proliferation were expected to be more strongly expressed in 
malignant than in benign tissue samples. Compared to our similar findings among Caucasian and 
Japanese subjects, other studies report lower levels of ER and PR expression in normal breast 
tissue of Asian women (110) and generally lower frequencies of ER-positive and PR-positive 
breast carcinomas in Asian than western women (111, 112). Our results disagree with these prior 
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reports, possibly due to the fact, that our Japanese women are 2nd to 4th generation immigrants, 
and in their risk pattern more similar to Caucasians. 
To our knowledge, no previous results for associations between mammographic density and ERβ, 
HER2/neu and PCNA have been reported. 
As in previous studies, we found percent breast density to differ significantly by age, menopausal 
status, HRT, BMI, parity and age at first live birth. The higher percent density among women with 
Japanese ancestry despite their lower breast cancer risk was also observed (38).  
This might be due to the smaller breast sizes which result in a higher percent of breast occupied by 
dense tissue. As shown in cross-sectional comparisons, the size of the dense area appears to be a 
better indicator of risk when different ethnic groups are compared (70, 71). 
Breast density has also been shown to be affected by cumulative lifetime estrogen exposure. Our 
findings agree with prior studies consistently reporting increased density with earlier age at 
menarche, later menopause, and use of combined HRT (42-44). 
In our analysis of breast density and hormonal and proliferative histopathologic markers in benign 
and malignant tissue samples, we did not observe any consistent significant association between 
markers and mammographic density. However, it appeared that mammographic density was 
slightly higher in women with PR expression (compared to no PR expression in tissue samples). 
Though not significant, this observation was consistent across the two major ethnic groups and 
tissue origins (malignant and benign tissue). The difference in benign samples was 3-4% in 
mammographic density which, if a true finding, may translate into a 6-8% higher breast cancer 
risk (113). 
Although we observed a higher percent density with expression of ERβ in the overall population as 
well as in Caucasian women, findings differed among Japanese subjects and in malignant 
samples. Given the inconsistent findings, and the fact that to date, no other studies have examined 
ERβ in its relation to density, future studies are needed to interpret a possible association.  
Furthermore, our findings of higher percent breast density in women with less extensive ERα 
staining are inconsistent with our hypothesis. The tentative findings among Japanese women and 
malignant samples of higher density with higher expression of ERα are not statistically significant 
and might be due to small numbers.  
To our knowledge, only one prior study assessed the association of ERα and PR expression with 
mammographic breast density and reports similar results (78). In noncancerous tissue from 
mastectomies of a relatively small study population (n=56), no association was found between ER 
or PR status and breast density (78). These findings agree with prior investigations that do not 
report any association of high risk pathologic changes or fibrocystic breast disease with 
mammographic breast density (32, 33, 114). 
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The slightly higher PR expression in women with high breast density that we observed in our study 
may reflect a stronger estrogenic response in mammographically dense breasts which might 
possibly lead to stronger cell proliferation. This hypothesis is supported by reports describing 
associations of breast density with hyperplasia and other proliferative lesions in breast tissue (4, 
29, 115).  
In benign samples, breast density was slightly higher for expression of Ki-67 and PCNA, both, in 
the overall study population and ethnic groups, except for PCNA among Caucasians. Density did 
not differ significantly with expression in malignant samples.  
Quite a few studies addressed the correlation of mammographic breast density and 
histopathological correlates of proliferation, using different sources for breast tissue. Most of these 
studies describe a positive association between breast density and proliferation in epithelial and 
stromal tissue components. In particular, a positive correlation between high density and 
intraductal epithelial hyperplasia and lobular microcalcification (28), and an association with high 
risk patterns such as atypia of the ductal type (24, 29, 30) and carcinoma in situ or atypical 
hyperplasia (115) have been described.  
This agrees with the hypothesis that high breast density is associated to higher breast cancer risk 
through mechanisms which contribute to the proliferative activity of breast tissue. A higher index of 
proliferation exposes more cells to potential environmental alteration and subsequent malignant 
conversion. To date, two studies examined mammographic density and Ki-67 expression; one 
reported no significant association (85), the other found a positive association (78). Harvey et al. 
found breast density to be associated to an increased Ki-67 activity in the ducts of breast tissue 
(p=0.031) (78), whereas the other investigation, which assessed FNA tissue samples of 344 pre- 
and postmenopausal women, did not find any association between density and Ki-67 expression 
(85).   
 
4.1.2 Density and stromal markers 
Besides the consistently reported association of density with proliferative lesion of the epithelium 
(23, 24, 30), density has also been found to correlate with intra- and extralobular fibrosis (29) as 
well as higher collagen density (88, 89). Since the stroma compromises most of the 
mammographically dense area, these associations might be of importance for the associated 
increase in breast cancer risk. 
Altered regulation of the stroma, or extracellular matrix (ECM), contributes to neoplastic 
progression and disruptions in the ECM, which possibly precede changes in the epithelium (90). 
Matrix metalloproteinases (MMPs), involved in the remodeling of ECM, contribute to multiple steps 
of tumor promotion, angiogenesis, and the establishment of metastatic lesions (116, 117). A 
44 
 
disruption of the balance between MMPs and their natural inhibitors (TIMPs) has been implicated 
in the progression of cancer (118). To our knowledge, no previous studies have examined MMPs 
and their effect on breast density as of this date. 
For MMP3 and MMP9 less than 20% of cells stained positive in different tissue origins. Therefore 
we did not include these markers in further analyses. MMP1 and MMP12 expression was higher in 
malignant than in benign samples, TIMP3 was more frequently expressed in benign stromal, but 
malignant epithelial tissue. Except for MMP12, which stained higher in Japanese women, 
expression of stromal markers was similar among different ethnicities.  
This exploratory study detected no statistically significant associations between mammographic 
density and expression of MMP1, MMP12, and TIMP3 in breast tissue. However, we found TIMP3 
to be consistently less expressed in breast tissue with high than low mammographic density. 
Despite its lack of statistical significance, the consistency of this trend across ethnic groups and 
tissue types may suggest an inverse association. Although for MMP1 and 12, no significant 
association with breast density was observed, the relations appeared to differ between Caucasian 
and Japanese women. Whereas the expression of markers differed little by ethnicity, higher MMP1 
expression was related to higher breast density among Caucasian women and was inversely 
related to breast density in Japanese women. These results were analogous in epithelial and 
stromal tissue as well as malignant and benign samples.  
Contrary to our findings, a previous study with a very small sample size found high breast density 
to be associated to an increased amount of TIMP3 (119). The authors hypothesized that TIMP3 
may influence matrix deposition leading to higher breast density or that TIMP3 may act through 
alteration of insulin-like growth factors, which influence cell proliferation. A possible explanation for 
the discrepancy of the two studies is that the balance between MMPs and TIMPs is more important 
than just the expression of one protein.  
MMPs are thought to be secreted not only by tumor cells, but mainly by the surrounding reactive 
microenvironment. These proteinases degrade the basement membrane and ECM components to 
a more “watery” consistence, which radiographically is denser than fat, which facilitates tumor 
invasion and formation of metastasis (90, 94). Thus, MMPs also contribute to early steps of tumor 
progression, including tumor promotion and angiogenesis (116, 117). As a result of the activity of 
MMPs, cell-cell and cell-ECM interactions are altered, new biologically active ECM molecules are 
generated, and the bioavailability and activity of many growth factors and cytokines is modified. We 
indeed found stronger expression of all MMPs in malignant than benign tissue. Our findings of 
higher MMP1 expression in Caucasian women with higher densities agree with the hypothesis that 
MMPs might contribute to the associated higher breast cancer risk in these women. MMP-1 is an 
interstitial collagenase that is often up regulated in breast cancer (120). Additionally, in vitro studies 
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show that MMP-1 facilitates the invasive properties of breast cancer cells (121). However, the 
opposing findings in Japanese women are difficult to explain; although breast cancer is less 
frequent in Japanese women, there is little difference in risk factors by ethnicity (table 5). Almost 
90% of our participants are born in the United States, most of these are probably at least second 
generation immigrants, so lifestyles and breast cancer incidence are more similar to Caucasian 
women.  
To thoroughly evaluate the role of MMP1, concise staining panels including its counterpart TIMP-1 
are needed. Because of the high number of comparisons the statistically insignificant differences 
might be due to chance or they may also indicate variation in genetic or other risk factors for breast 
cancer across ethnic groups.  
 
Growing evidence supports the notions that altered regulation of the extracellular matrix 
contributes, in a causal matter, to neoplastic progression. An imbalance between MMPs and their 
inhibitors has been found to be a factor in different steps of tumor growth (94, 118). Therefore, a 
role for MMPS and TIMPs in the association between mammographic breast density and breast 
cancer risk as well as survival appears likely. 
Overexpression of TIMPs has been shown to inhibit primary tumor growth in mice (122, 123) as 
well as reduce tumor invasion and metastasis (118, 124, 125). In the present study, TIMP3 
expression was lower in stromal cells of malignant than benign tissue; however, this was not the 
case for epithelial cell expression. One possible hypothesis would be that the lower expression of 
TIMP3 in women with high breast density may indeed affect the activity of different growth factors 
and influence matrix deposition that translates into altered breast density. If low TIMP expression 
leads to greater MMP activity, which in turn may lead to higher breast density and a greater 
carcinogenic potential of breast cells, it may be partially responsible for the increased breast 
cancer risk associated with high breast density or with further progression and greater mortality. 
However, TIMP3 also has other specific bio-cellular functions, not related to MMP-inhibition, such 
as direct induction of apoptosis (118, 126) or inhibition of endothelial cell motility and proliferation 
(127) which might also be possible mechanisms leading to low breast density and associated 
breast cancer risk.  
 
4.2 Strength and limitations 
The benefits and drawbacks of TMA-technology have been discussed in detail in other publications 
by Hernandez and colleagues (128). One disadvantage of the TMA approach is the loss of 
samples during immunohistostaining due to lack of adhesion to the glass slides. This might be due 
to the small diameter (0.6 mm) used in our study and larger cores might reduce these losses. 
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Another issue with TMAs is the confounding that might have taken place throughout the 
preparation of TMAs. When choosing a section on the slide for construction of a TMA, no effort 
was made to distinguish between specific areas of the tumor (center versus periphery, depth of 
invasion, et cetera). Bias due to intratumor heterogeneity may have been introduced when these 
small pieces of tissue were selected. Also, sectioning these constructed TMA blocks might lead to 
a depletion of the tumor, leaving only the first slides with useable tissue specimens (about 1 to 25 
slides are said to contain tumor tissue). Subsequently cut slides might not contain sufficient tumor 
tissue and therefore decrease the accuracy of results.  
Though these issues might be important concerns in studies directly assessing tumor variables, 
these differences are not likely to have a big impact on our analysis, because we used 4 different 
cores of each tumor block to assure consistency of findings. To further reduce the risk of 
misclassification, we also reassessed TMAs after staining as to ensure tissue entity (benign vs. 
malignant tissue). As shown before, benign tissue samples had to be reclassified more often than 
malignant cores (129, 130). There might also be differences in the staining results due to different 
tissue fixation and storage procedures used in the several hospitals, from which we received the 
tissue blocks.  
Additionally, there might be some measurement inaccuracy in the analysis of slides which 
contained a lot of inflammatory cells. When choosing the negative stained epithelial cells (light and 
dark blue color), granulocytes and mastocytes would simultaneously be marked as well. However, 
only very few slides included tumors that showed a high amount of inflammation. All slides of one 
study part (i.e. histopathological marker) were read by one person, assuring consistency in our 
results. Even though the exact amounts of positively or negatively stained cells might differ slightly, 
the analyses for each marker were still correlated.  
Our investigation illustrates the problems of obtaining benign breast tissue specimens for a 
representative sample of participants in epidemiologic research. We acknowledge that breast 
tissue considered normal or benign in this study represents specimens from women diagnosed 
with breast cancer. Therefore, these samples may not be equivalent to breast tissue from women 
with no clinical or mammographic abnormalities. Breast cancer is considered a systemic disease, 
and even in the absence of cancer, breast tissue obtained from biopsies may be different from 
tissue of women not requiring a biopsy. It is rather unfortunate, that past research addressing 
density and histopathologic markers in healthy women is limited to forensic studies (23) and 
investigations of breast reduction samples (131). Our study would have benefited from tissue 
samples from healthy women, but constraints for obtaining human breast tissue samples for 
research projects limit this approach. The amount of material available from stereotactic biopsies is 
often too small for TMA preparation, and women with benign biopsies cannot be identified through 
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tumor registries. Although breast reduction surgery would yield large amounts of tissue, women 
undergoing that procedure represent a selected subgroup with predominantly fatty breast tissue 
and different mammographic patterns (132).  
As to the pilot nature of this project, we chose our array of MMPs based on review of the literature 
regarding relevance to breast cancer, availability of antibodies and prior staining experience at our 
institution. Our choice of markers represents only part of the markers that are needed for a concise 
evaluation of MMP and TIMP activity. Therefore one major disadvantage of our study is the 
incompleteness of MMP panels. In particular the low staining results of MMP9 and MMP3 might be 
due to high levels of TIMP-1, their natural inhibitor, which needs to be assessed in future studies 
for a thorough understanding.  
Although mammographic density assessment is a well established technique, some limitations 
need to be mentioned. While assessing mammographic density, differences in the quality of films 
in respective clinics and between subjects may have introduced some measurement error. The 
level of compression of the breast, the amount of radiation as well as the processor chemistry used 
during mammography introduce possible confounding. Through differences in assessing density, 
breast cancer risk might be underestimated. Densities also differ on digital and film mammograms. 
However, these differences are minimal. We chose a density measurement technique that is 
currently the highest standard with consistently reported interreader reliability (ICCs) of 0.9 and 
higher. 
For development of future measurement techniques, it has been criticized that the two-dimensional 
projection used in mammography is limited in terms of measuring a three-dimensional tissue 
feature such as density. A technique that determines the total glandular content form a three-
dimensional construction of the breast might give a better estimation of breast density. Pixels are 
only used in a binary fashion, either representing fat or parenchyma. Therefore pixels with large 
amounts of parenchyma are seen equal to pixels with small quantities of parenchym. Several three 
dimensional techniques are under investigation (133, 134). 
Given a sample size of 78 women in our smallest subgroup, α = 0.05 (two-sided) and power = 
0.80, a standard deviation of 22.2 for percent breast density, the minimum detectable difference in 
means is 11%. Since this was a pilot-project in this particular field of research, we are aware that 
the power is low and some results may only be suggestive.  
 
On the other hand, this study had several strengths. Our distinctive study population included a 
large sample of breast cancer cases with ethnic diversity and pathologic specimens from a 
population-based tissue repository. The availability of demographic and other risk factor variables 
in a study of tissue characteristics is rather unique and gives us the opportunity to apply suitable 
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adjustments to our analyses. The women in this investigation also span a wide age range which 
includes menopause and important feature when assessing breast density.  
The questionnaires collecting data from our participants were designed and tested by highly 
trained staff at the cancer center. Furthermore, mammograms were obtained before the 
participants were diagnosed with breast cancer, which gives us the opportunity to assess density 
on mammograms without confounding by tumor masses.  
This study benefited form the use of a high throughput TMA approach which enabled us to assess 
marker expression in a large number of samples under comparative conditions. Additionally, 
multiple markers could cost-effectively be analyzed using sections of the TMA block without 
depletion of the original tissue blocks for future research. Previous studies report a nearly 100% 
concordance between TMA data and data from staining of corresponding whole-section tumor 
slides (135-137). The investigation adds to the limited literature of TMAs in epidemiologic studies 
and to the variety of markers measured in TMAs (128, 129).  The access of tumor blocks through 
tumor registries will allow future population-based research with pathologic specimens.  
 
4.3 Implications and future research 
To benefit from the advantages of the TMA technique in future research, it is recommended that a 
trained pathologist carefully selects the areas for subsequent TMA preparation and to minimize the 
loss of specimens during immunostaining. Especially the loss of benign tissue samples during 
staining seriously limited our power to detect associations with breast density. Using cores with a 
larger diameter could possibly alleviate this problem and the pathologist needs to be very careful in 
marking benign areas. Alternatively, immunohistochemistry could be performed on full sections, if 
available, but may be unacceptable because blocks will be used up. Constructing TMAs from large 
cohorts of patients in future clinical studies offers a useful tool for the association between 
biomarkers and clinically important end-points, as well as screening of potentially promising new 
biomarkers (138, 139).   
To further assess multiple pathways such as inflammation, proliferation, apoptosis and hormonal 
pathways possibly associated with breast density, gene expression studies may be a more efficient 
technique. Many different signaling pathways controlling cell proliferation, differentiation and death 
are involved in cancer development. A powerful tool for analyzing multiple pathways 
simultaneously is the analysis of gene expression with microarrays. In recent years, gene 
expression profiling has successfully been used in breast cancer research and has, for instance, 
indentified distinct subtypes of breast cancer with expression profiles, representing biologic entities 
with differences in clinical outcome (140, 141). The use of this technique particularly in cancer 
research has clearly been shown in numerous studies (142-144). Analyzing gene expression at 
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different stages of cancer development and in women with different risk factors, such as the 
amount of dense tissue in their breasts, could give valuable insight in disease processes.  
 
Based on our few suggestive findings, future mammographic density investigations may pursue 
estrogenic effects as assessed by PR and cell proliferation using Ki-67 and other such markers to 
examine the question of local estrogen activity in relation to breast density.  
Given the weak associations in the current investigations and the discrepant findings across 
studies, the roles of hormonal receptors and growth factors in shaping breast density deserve 
further attention (87, 89).   
No prior investigations have examined the association of mammographic density with MMPs. This 
novel approach showed trends which might suggest a possible association of breast density with 
MMPs and TIMPs. However, to fully understand the role of MMPs and their inhibitors, it is of 
utmost interest to study complete panels of these markers. In particular MMP2, MT1-MMP, TIMP-1 
and TIMP-2 would be desirable stains to study. Future investigations into activities and ratios of 
these proteases as well as other pathways such as inflammation, may lead to identification of 
patients at high risk for developing breast cancer or developing remarkably aggressive 
tumors (145).  
Due to small sample sizes, we could only stratify our analyses by Japanese and Caucasian 
ethnicity. The issue of difference in ethnic groups needs to be addressed by future studies with 
larger numbers.  
 
Although breast density has consistently been shown to be strongly associated with breast cancer 
risk, the reasons or biological mechanisms for this positive association are largely unknown. In 
addition, there is no general agreement on what causes some women‟s breasts to be 
mammographically more dense than others. More importantly we do not know if a reduction in 
breast density would mean a reduction in risk, too. Cuzick et al. report a reduction in percent 
density and a subsequent reduction in breast cancer incidence with use of tamoxifen, a drug with 
antiestrogenic effects on breast tissue (146). In comparison, as described in detail above, HRT 
with combined regimens leads to an increase in percent density. Density could be an indicator of 
the cumulative breast cancer risk after exposure to different risk factors such as past estrogen 
exposure. Through its distinctive capability of being modifiable, it might also be a potential 
response biomarker. 
 
If the underlying pathology for mammographic density were better understood, prediction of breast 
cancer risk in individuals could allow for improved design of preventive strategies, planning of 
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interventions and improved clinical decision making. For instance in cardiovascular medicine, 
modification of risk factors based on risk prediction has been estimated to account for 
approximately half of the 40% reduction in age-specific mortality from cardiovascular 
disease (147). For breast cancer risk prediction, the Gail model is currently most widely used. This 
model includes age, age at menarche, age at first live birth, number of benign breast biopsies and 
number of first-degree relatives with breast cancer (148). The addition of percent mammographic 
density, as one of the strongest risk factors, to the Gail model might lead to more precise risk 
estimation. Addition of percent density as measured by BI-RADS, however has only shown modest 
levels of individual prediction, increasing the concordance statistics from ranges between 0.58 and 
0.63 to ranges between 0.62 and 0.66 (149). However, this increase is higher than an addition of 
the seven SNPs (single nucleotide polymorphisms) found reproducibly to be associated with breast 
cancer (concordance statistics: 0.63) (150).  
 
Further research in this area might be productive in providing a better understanding which is 
needed if density is to be used to estimate individual risk and to monitor changes in a meaningful 
way.  
The vast clinical use of screening mammography offers unique research potential for preventive 
studies. Mammograms are available for large numbers of women and acquired with comparable 
techniques. With the availability of prediagnostic mammograms, it would be reasonable to 
reanalyze breast cancer clinical trials for differences in outcomes according to breast density. Few 
studies have addressed recurrence rates after breast-conserving surgery and report positive 
associations of higher density with local recurrences (151, 152). Furthermore if would be of interest 
to study the possible effects of breast density on breast cancer survival.  
If exact mechanisms were known about the underlying pathology for increased breast density and 
increased breast cancer risk, medications acting on these specific mechanisms could be 
developed to decrease breast density and possibly also decrease the associated risk for breast 
cancer.  
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5. Summary 
Background. Mammographic breast density is a strong, independent risk factor for breast cancer, 
yet the underlying biologic mechanisms are not clear. Studies inconsistently report associations of 
breast density with histopathologic correlates including proliferative lesions of the epithelium, 
stroma or both. Matrix metalloproteinases (MMPs), endopeptidases regulating degradation of 
extracellular matrix play an important role in tumorigenesis and cancer progression. Imbalance of 
MMPs and their inhibitors might be a mechanism contributing to the elevated breast cancer risk 
among women with high densities. We explored the association of mammographic density, with 
hormonal, proliferative and stromal histopathologic markers in benign and malignant tissue from 
tumor blocks of breast cancer patients and the possible use of pathology blocks and TMA-
technology in epidemiological research. 
 
Methods. We recruited 283 cases from a case-control study on breast density. Mammographic 
density was assessed on digitized prediagnostic mammograms using a computer-assisted method. 
For 279 participants of the original study with primarily Caucasian (36%) and Japanese (41%) 
ancestry, we obtained tumor blocks and prepared tissue microarrays (TMA). Up to 4 malignant and 
4 benign cores per woman were placed in the TMA block; slides were immunohistochemically 
stained for ERα and ERß, PR, HER2/neu, Ki-67, and PCNA. At least one benign core could be 
assessed for 159 women, one malignant core for 253 women. In a second part of this study, we 
investigated the association of breast density with stromal and epithelial expression of MMPs 1, 3, 
9, and 12 and a tissue inhibitor of MMP3 (TIMP3). In the stromal marker datasets, there were 259 
women with at least one benign and 274 with at least one malignant measurement. The 
microscopic pathological evaluation categorized each core as no, weak, and strong staining 
(depending on the specific marker). We applied general linear models to compute breast density 
according to marker expression while adjusting for known confounders. 
 
Results: For staining of hormonal and proliferative markers a substantial proportion of the samples 
were in the low or no staining categories (range of 0-10%). None of the results were statistically 
significant, but women with PR and ERß staining had 3.4% and 2.4% higher percent density. The 
respective values for Caucasians were 5.7% and 11.6% but less in Japanese women (3.5% and -
1.1%). Percent density was 3.4% higher in women with any Ki-67 staining and 2.2% in those with 
positive PCNA staining.  
Strong expression of all MMPs was about twice as high in malignant as compared to benign tissue, 
while TIMP3 expression was higher in benign cores. For MMP3 and 9, less than 10% of cores 
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stained positive; thus, they were not further analyzed. No statistically significant association of 
TIMP3, MMP 1 or 12 with breast density was found. However, mean density was consistently lower 
with more extensive TIMP3 expression both in epithelial and stromal tissue of Japanese and 
Caucasian women. In particular, in benign epithelial tissue, mean density was 43.9% vs. 31.4% for 
no vs. strong stain (p=0.09); the respective values for malignant epithelial tissue were 39.2% vs. 
31.9% (p=0.18). Although overall results were non-significant for MMP-1, we noted a discrepant 
association by ethnicity. In Japanese women, density was inversely associated with MMP-1 
expression (31.5% for any stain vs. 41.3% for no stain in malignant stromal tissue; p=0.04). The 
same trend, though non-significant, was observed in all other tissue categories. In contrast, density 
was higher in Caucasian women with more extensive MMP1 expression; the respective values for 
malignant stromal tissue were 35.4% vs. 20.9% (p=0.11). 
 
Conclusions. This study detected little evidence for an association between mammographic density 
and expression of hormone receptors and proliferation markers in breast tissue, but it illustrated 
the problems of locating tumor blocks and benign breast tissue samples for epidemiologic 
research. Given the suggestive findings, future studies examining tissue estrogen levels, steroid 
receptors, and density in the breast may be informative. Our findings indicate that breast density 
may be related to higher proliferative activity through lower TIMP3. For MMP 1 and 12, no 
consistent association with breast density was observed. These data suggest possible 
mechanisms that may mediate the higher breast cancer risk in women with dense breasts and 
may, in the future, lead to preventive medications that lower mammographic breast density. Further 
studies of concise MMP and TIMPs panels and gene expression studies might lead to a better 
understanding of the underlying mechanisms. 
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6. List of abbreviations 
 BI-RADS Breast Imaging Reporting and Data System 
BMD Bone mineral density 
BMI Body mass index 
CEE Conjugated equine estrogens 
CIS Carcinoma in situ 
DCIS Ductal carcinoma in situ 
ECM Extra cellular matrix 
ER Estrogen receptor 
FFPE Formalin-fixed paraffin embedded 
FFQ Food frequency questionnaire 
Fig. Figure 
H&E Hematoxylin and Eosin 
HER-2/neu Human epidermal growth factor receptor 2 
HRT Hormone replacement therapy 
HTR Hawaii Tumor Registry 
ICC Intraclass correlation coefficient 
IGF Insulin-like growth factor 
IGFBP Insulin-like growth factor binding protein 
IHC Immunohistochemistry 
IRB Institutional review board 
MEC Multi ethnic cohort 
MMP Matrix metallo proteinase 
NAF Nipple aspirate fluid 
NCC Nested case control 
PCNA Proliferating cell nuclear antigen 
PR Progesterone receptor 
s.c. Sub cutaneous 
SEER Program Surveillance, Epidemiology and End Results Program 
SNP Single nucleotide polymorphism 
TAC Tissue advisory committee 
TIMP Tissue inhibitor of metalloproteinases 
TMA Tissue micro array 
VEGF Vascular endothelial growth factor 
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